Fact-checked by Grok 2 weeks ago

Methoxsalen

Methoxsalen, chemically known as 9-methoxy-7H-furo[3,2-g]chromen-7-one, is a naturally occurring linear furocoumarin extracted from plants such as Ammi majus and employed as a photosensitizing agent in photochemotherapy.^[1] It is administered orally or topically in conjunction with controlled ultraviolet A (UVA) radiation, a regimen termed PUVA therapy, for the treatment of severe, recalcitrant dermatoses including psoriasis and vitiligo.^[2]^[3] The therapeutic mechanism involves methoxsalen's absorption into skin cells, where UVA irradiation activates it to intercalate between DNA base pairs and form covalent photoadducts, predominantly with thymine residues, resulting in DNA cross-linking that inhibits replication and transcription, thereby reducing hyperproliferative epidermal activity.^[1] Clinical efficacy is evidenced by clearance rates exceeding 80% in psoriasis patients after 20-30 sessions, though relapse often necessitates maintenance therapy.^[4] Despite these benefits, PUVA with methoxsalen is associated with dose-dependent risks, including erythema, nausea, and premature aging, as well as elevated incidence of non-melanoma skin cancers and potential melanoma after prolonged exposure, leading to its classification as a known human carcinogen by the National Toxicology Program.^[5]^[1] Use is thus restricted to specialized settings with rigorous monitoring to mitigate oncogenic hazards.^[3]

Chemical and Biological Properties

Molecular Structure and Natural Sources

Methoxsalen, systematically named 9-methoxy-7H-furo[3,2-g]chromen-7-one, is a linear furocoumarin classified within the psoralen family of compounds.^[6] It features a tricyclic structure comprising a coumarin moiety fused to a furan ring, with a methoxy substituent at the 9-position that contributes to its inherent photoactivity upon exposure to ultraviolet light.^[6] The molecular formula is C12H8O4, and its molecular weight is 216.19 g/mol.^[7] This compound is naturally produced by various plants as a secondary metabolite, primarily serving defensive roles against environmental stressors. Methoxsalen is most abundantly sourced from the seeds of Ammi majus (bishop's weed), an umbelliferous plant native to the Mediterranean region, where it can be extracted through solvent-based methods such as benzene-ethyl acetate partitioning followed by evaporation and purification.^[8] ^[9] It also occurs in the seeds of Psoralea corylifolia, a leguminous plant used in traditional medicine across Asia.^[10] Trace quantities of methoxsalen are detectable in common edible plants and fruits, including citrus species such as limes, as well as figs, celery, and parsnips, belonging to families like Rutaceae and Apiaceae.^[2] ^[6] In these botanical contexts, furocoumarins like methoxsalen function as phytoalexins, providing constitutive and inducible protection against herbivory and ultraviolet radiation, with synthesis often upregulated in response to UV exposure in surface tissues.^[11] ^[12] This defensive adaptation deters specialist herbivores and pathogens by interfering with their metabolic processes upon activation.^[13]

Biosynthesis Pathways

The biosynthesis of methoxsalen, a linear furanocoumarin also known as xanthotoxin or 8-methoxypsoralen, originates from the convergence of the phenylpropanoid pathway—yielding the coumarin core umbelliferone—and the mevalonate pathway, which supplies the C5 prenyl unit dimethylallyl pyrophosphate (DMAPP). This integration reflects the plant's assembly of aromatic and isoprenoid moieties into bioactive secondary metabolites, with enzymatic steps localized primarily in endoplasmic reticulum membranes of specialized cells.^[14]^[15] Umbelliferone (7-hydroxycoumarin) forms the foundational scaffold via activation of p-coumaric acid (derived from L-phenylalanine by phenylalanine ammonia-lyase and cinnamate 4-hydroxylase) to its CoA thioester, followed by 2'-hydroxylation at the cinnamoyl side chain catalyzed by a 2-oxoglutarate-dependent dioxygenase or cytochrome P450 (e.g., CYP98A), and spontaneous or enzyme-aided lactonization.^[16] This step establishes the benzopyrone ring system essential for downstream furan ring formation. From umbelliferone, C-prenylation occurs at the electron-rich C-6 position via a membrane-bound prenyltransferase (e.g., umbelliferone:DMAPP 6-O- or C-prenyltransferase, such as AsPT1/AsPT2 in Ammi majus), incorporating DMAPP to produce demethylmarmesin (6-prenylumbelliferone). The prenyl side chain then undergoes terminal epoxidation by a cytochrome P450 monooxygenase (e.g., CYP736A subfamily), generating the epoxyprenyl intermediate marmesin.^[17]^[15] Marmesin is transformed into psoralen through oxidative ring closure and carbon chain rearrangement by psoralen synthase, a cytochrome P450 enzyme (e.g., CYP71AJ1 in Peucedanum praeruptorum or equivalent in Apiaceae), which cleaves the epoxide via syn-elimination, releasing acetone as a byproduct and fusing the furan ring in linear orientation (furo[3,2-g] configuration).^[18] Psoralen subsequently undergoes regioselective hydroxylation at C-8 by a psoralen 8-monooxygenase (cytochrome P450, e.g., CYP82M1-like), yielding xanthotoxol, which is then methylated at the phenolic oxygen by an S-adenosyl-L-methionine-dependent O-methyltransferase to form methoxsalen.^[19]^[14] Empirical validation from isotopic labeling experiments, including feeding [¹⁴C]-L-phenylalanine (incorporating into the coumarin ring) and [³H]-mevalonic acid (labeling the furan C5 unit), demonstrates near-quantitative flux through these precursors in producing furanocoumarins like methoxsalen, with dilution factors indicating minimal alternative routes.^[19] Pathway variations exist across species; for example, in Ammi majus, fungal elicitors upregulate membrane-associated prenyltransferases and synthases, enhancing flux, while in Rutaceae, distinct prenyltransferase isoforms favor angular furanocoumarins over linear ones like psoralen derivatives.^[17]

Pharmacology

Mechanism of Action

Methoxsalen, a linear furocoumarin, initially binds to double-stranded DNA through non-covalent intercalation between base pairs, exhibiting a preference for 5'-TpA sequences that facilitate subsequent photoreactivity.^[2] This intercalation positions the drug's furan and pyrone rings adjacent to pyrimidine bases, particularly thymine, without initial covalent attachment.^[20] Upon exposure to ultraviolet A (UVA) radiation in the 320-400 nm wavelength range, methoxsalen absorbs photons, transitioning to an excited triplet state that enables cycloaddition reactions. The primary photochemical reaction involves a 4',5'-cycloaddition between the furan double bond of methoxsalen and the 5,6 double bond of pyrimidine bases, forming covalent monoadducts that distort the DNA helix.^[21] These monoadducts can progress to interstrand crosslinks if a second UVA-induced reaction occurs at the 3,4 pyrone double bond with an opposing pyrimidine on the complementary strand, thereby blocking DNA strand separation.^[22] The formation of these photoproducts has been empirically confirmed through steady-state and time-resolved spectroscopy, which detect spectral shifts indicative of adduct binding, as well as techniques like gel electrophoresis for visualizing DNA crosslink-induced mobility changes.^[23]^[24] These DNA lesions inhibit replication and transcription by impeding polymerase progression and RNA polymerase activity, respectively, with crosslink efficiency increasing in a dose-dependent manner relative to methoxsalen concentration and UVA fluence.^[2] In hyperproliferative cells such as keratinocytes, the accumulated damage activates apoptotic pathways, including cytochrome c release and caspase activation, selectively targeting rapidly dividing populations over quiescent ones.^[25]^[20]

Pharmacokinetics and Metabolism

Methoxsalen is rapidly absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations typically reached within 1.5 to 3 hours, though this varies by formulation—conventional capsules achieve peaks in 1.5 to 6 hours, while liquid-filled capsules do so in 0.5 to 4 hours.^[1]^[26] Absorption is generally high and variable, with liquid formulations exhibiting 1.5- to 2-fold greater area under the curve and 2- to 3-fold higher peak levels compared to conventional capsules; concomitant food intake further enhances extent and peak absorption.^[26]^[27] Topical application limits systemic absorption, primarily confining the drug to the site of application for localized effects, with photosensitivity persisting for several days but minimal plasma exposure.^[26] The drug distributes widely, with a volume of distribution ranging from 1 to 9 L/kg, and is 75–91% bound to serum proteins, predominantly albumin.^[26]^[27] It preferentially accumulates in epidermal cells and distributes proportionally to serum levels in tissues such as the eye lens.^[1]^[26] Methoxsalen undergoes rapid and extensive hepatic metabolism, with high intrinsic clearance leading to near-complete conversion to inactive metabolites, including demethylation to 8-hydroxypsoralen followed by conjugation with glucuronic acid and sulfate.^[26]^[27] The plasma elimination half-life is approximately 0.5 to 2.4 hours.^[26]^[27] Elimination occurs predominantly via the kidneys, with 80–90% of the dose excreted as metabolites in urine within 8 hours and over 95% within 24 hours; less than 0.1% is eliminated unchanged.^[1]^[26] Pharmacokinetics exhibit substantial interindividual variability, including clearance rates from 40 to 650 L/h, largely attributable to differences in hepatic metabolic capacity.^[27]

Medical Applications

Primary Indications

Methoxsalen is primarily indicated for the treatment of severe, recalcitrant psoriasis in patients who have failed to respond adequately to topical corticosteroids or other conventional therapies, administered orally or topically in conjunction with controlled exposure to ultraviolet A (UVA) radiation as part of psoralen plus UVA (PUVA) photochemotherapy.^[1]^[2] This approach is reserved for disabling cases where empirical evidence from controlled studies demonstrates significant plaque clearance, typically exceeding 75% improvement in affected areas among non-responders to first-line treatments.^[1] For vitiligo, methoxsalen is approved for repigmentation in extensive or generalized cases unresponsive to topical agents, again requiring combination with UVA to activate its photosensitizing effects and promote melanocyte stimulation.^[1]^[28] Patient selection emphasizes widespread depigmentation where UVA dosing is calibrated to minimize burns while achieving therapeutic photoconjugation in skin.^[1] In cutaneous T-cell lymphoma (CTCL), particularly mycosis fungoides stages IA to IVA, methoxsalen is indicated for extracorporeal photopheresis using the sterile solution formulation (e.g., Uvadex), where leukocytes are exposed to UVA ex vivo after methoxsalen uptake to induce apoptosis of malignant cells before reinfusion.^[29]^[30] This modality targets circulating atypical lymphocytes in erythrodermic or widespread disease refractory to standard chemotherapies.^[29] Systemic PUVA variants may also apply for plaque-stage CTCL, distinguishing from localized topical applications limited to thin plaques or palmoplantar involvement.^[31]

Administration Protocols

Methoxsalen is primarily administered orally for PUVA therapy, with a standard dose of 0.4 to 0.6 mg/kg body weight taken 1 to 2 hours before UVA exposure to allow peak plasma levels during irradiation; ingestion with milk or low-fat food minimizes gastrointestinal upset.^[5]^[31] For topical application in bath PUVA, a 0.2% methoxsalen lotion is diluted in bathwater (typically 1-5 mg/L concentration), with patients soaking affected areas for 15 minutes followed by UVA exposure 15-30 minutes later to target localized lesions while reducing systemic absorption.^[32]^[33] Initial UVA dosimetry starts at the minimal erythema dose (MED), often 0.5 to 1.5 times the patient's determined MED (equivalent to 1-3 J/cm² depending on skin phototype), with subsequent increments of 0.5-1 J/cm² per session based on response and Fitzpatrick skin type to prevent overexposure in lighter types (I-III).^[1] Treatments occur 2-3 times weekly on nonconsecutive days, with cumulative UVA doses monitored to cap at 1000-1500 J/cm² lifetime exposure per patient to mitigate overdose risks, adjusting frequency downward during maintenance phases.^[26]^[34] Patients must wear UVA-blocking wraparound sunglasses for 24 hours post-oral dosing to protect eyes from phototoxicity, and eyes should be shielded during UVA sessions; due to demonstrated teratogenicity in animal models and limited human data, effective contraception is required for women of childbearing potential throughout therapy and for at least one menstrual cycle afterward.^[1] Dosing and UVA adjustments incorporate Fitzpatrick skin type classification, with lower starting exposures (e.g., 1.5 J/cm² for types I-II) versus higher for darker types (up to 3 J/cm² for V-VI) to optimize efficacy while minimizing burn risk.^[35]

Clinical Evidence and Efficacy

Key Clinical Trials and Outcomes

One of the earliest multicenter clinical trials evaluating oral methoxsalen combined with UVA (PUVA) therapy for moderate-to-severe psoriasis, conducted in the mid-1970s across multiple U.S. centers involving over 1,300 patients, reported clearance rates of 88% after an average of 25 treatments, defined as near-complete resolution of psoriatic plaques confirmed by clinical assessment and histopathology showing reduced epidermal hyperplasia.^[36] Subsequent analyses of this cohort demonstrated that 70-90% of responders maintained remission for at least 6 months post-treatment, with histopathological evaluations revealing normalization of keratinocyte proliferation and decreased rete ridge elongation in cleared lesions.^[37] The prospective PUVA Follow-up Study, tracking 1,380 patients with severe psoriasis treated initially between 1975 and 1977, provided long-term efficacy data through serial assessments over decades; at 4 years post-clearance, approximately 27% remained free of disease without maintenance therapy, while relapse rates averaged 50-60% within 1-2 years, quantified by persistent elevations in Psoriasis Area and Severity Index (PASI) scores above 5 in non-remitters.^[36] In a randomized controlled trial of bath PUVA using methoxsalen for plaque psoriasis, 80.4% of patients achieved at least 75% PASI reduction (PASI-75) after a median of 30 sessions, with histopathological confirmation of attenuated epidermal acanthosis in responders.^[38] For vitiligo, a 2006 cohort study of 51 Israeli patients treated with oral PUVA over 2-10 years reported repigmentation in 56% of cases, with 20-40% sustaining partial to complete follicular repigmentation at 5-year follow-up, assessed via standardized body surface area measurements and Wood's lamp evaluation showing stable melanocyte recolonization.^[39] A randomized trial comparing PUVA variants in generalized vitiligo demonstrated mean body surface area reductions of 46.4% after 36 months, corroborated by biopsy-proven increases in dermal melanin and reduced depigmented patch expansion rates.^[40] These outcomes highlight PUVA's capacity for inducing histopathological reversal of melanocyte loss, though individual variability in sustained response was noted across ethnic groups.^[41]

Comparative Effectiveness

Methoxsalen-enhanced PUVA therapy demonstrates superior short-term clearance rates compared to narrowband UVB (NB-UVB) phototherapy in treating plaque psoriasis, with meta-analyses reporting complete clearance in approximately 80% of PUVA patients versus 70% for NB-UVB.^[42] Randomized trials corroborate this, showing clearance in 84% of PUVA-treated patients versus 65% with NB-UVB, though PUVA often requires more sessions and higher cumulative doses.^[43] PUVA also offers extended remission durations without maintenance, with median relapse times of 8 months compared to 4 months for NB-UVB, and sustained clearance in 35% of patients at 6 months post-treatment versus 12% for NB-UVB.^[43]^[44] In comparisons with biologics such as etanercept or infliximab, indirect evidence from registry data indicates PUVA achieves comparable or superior PASI reductions in moderate-to-severe psoriasis, without the systemic immunosuppression associated with TNF inhibitors.^[45] Head-to-head trials are limited, but PUVA's efficacy aligns with biologics in skin clearance while avoiding risks like opportunistic infections.^[46] Cost-effectiveness analyses favor PUVA, particularly in resource-constrained settings, with 3-year phototherapy costs around $5,000 versus over $180,000 for biologics like secukinumab, driven by lower drug acquisition and administration expenses.^[47] PUVA lacks broad superiority across psoriasis subtypes or patient profiles; biologics outperform in cases with psoriatic arthritis comorbidities due to targeted joint efficacy, and PUVA's clinic-based protocol reduces convenience compared to self-injectable biologics.^[46] Relapse risks remain elevated for PUVA without ongoing maintenance in refractory cases, underscoring its role as an effective but adjunctive option rather than first-line for all scenarios.^[48]

Safety Profile

Acute Adverse Effects

Nausea is the most frequently reported gastrointestinal adverse effect of oral methoxsalen, affecting approximately 15% of patients undergoing PUVA therapy, and is typically dose-dependent with peak onset 1-2 hours post-ingestion.^[49] ^[1] This symptom can be mitigated by administering the drug with milk or food, which delays absorption and reduces peak plasma levels.^[1] Headaches may also occur concurrently in some cases.^[50] Dermatologic reactions predominate among acute skin effects, including pruritus in about 15% of patients and mild, transient erythema appearing 24-48 hours after UVA exposure, which is an expected therapeutic response indicating photosensitization.^[49] ^[51] More severe phototoxicity, manifesting as burning or blistering, arises from UVA overdose, patient non-compliance with post-treatment sun avoidance, or excessive dosing, potentially leading to second-degree burns in vulnerable cases.^[26] ^[52] Such incidents are uncommon but underscore the need for precise dosimetry and shielding.^[53] Ocular exposure without protective goggles risks acute photokeratitis, characterized by painful inflammation of the corneal epithelium due to methoxsalen-UVA interaction, though this is largely preventable with mandatory eyewear during and for 24 hours following treatment.^[54] Allergic contact dermatitis from psoralens occurs rarely, in less than 1% of treated patients.^[55]

Long-Term Risks and Carcinogenicity

Methoxsalen, when used in psoralen plus ultraviolet A (PUVA) therapy, exhibits a dose-dependent association with elevated risk of squamous cell carcinoma (SCC), with epidemiological data indicating relative risks of 2 to 5 or higher following cumulative exposure exceeding 200 treatments. In the prospective PUVA Follow-up Study involving psoriasis patients, the incidence rate ratio for SCC was 5.9 (95% CI, 4.0-8.7) for high-dose exposure (>200 treatments or >2000 J/cm²) compared to low-dose, based on pooled analysis across multiple cohorts showing zero SCC events in low-exposure groups during 8-13 years of follow-up but rates up to 65 per 1000 person-years in high-exposure cases.^[56] This causality aligns with methoxsalen's photosensitizing effects, which, combined with UVA, induce DNA adducts and mutagenesis in keratinocytes, as evidenced by consistent dose-response patterns in long-term registries spanning over 25 years.^[56] Malignant melanoma risk similarly demonstrates latency and dose-dependency, with no significant elevation observed within the first 15 years post-initiation but a marked increase thereafter, particularly in high-exposure cohorts receiving 250 or more treatments. Among 1,380 psoriasis patients tracked for 22,104 person-years in a multicenter cohort, the overall relative risk was 2.3 (95% CI, 1.1-4.1), rising to 5.4 (95% CI, 2.2-11.1) after 15 years, with an incidence rate ratio of 4.1 (95% CI, 1.3-13.4) for those exceeding 250 treatments versus fewer.^[57] Extended follow-up from PUVA registries confirms this pattern, attributing the risk to persistent psoralen-induced melanocytic mutations accumulating over decades.^[57] In male patients, unprotected genital exposure during PUVA sessions has been causally linked to heightened incidence of genital SCC, including scrotal variants, with high-exposure groups (≥40 treatments per year) exhibiting a 286-fold relative risk compared to the general population and 16.3-fold versus low-exposure PUVA recipients.^[58] This dose-response effect, independent of UVB adjuncts, underscores the vulnerability of non-shielded mucosal and thin-skinned areas to photocarcinogenesis from circulating methoxsalen.^[58] Prolonged PUVA involving methoxsalen also induces premature skin aging through mechanisms akin to chronic UVA photodamage, resulting in permanent dermal changes such as elastosis and collagen fragmentation, which degrade extracellular matrix integrity and mimic solar elastosis histologically.^[59] Longitudinal observations from treatment cohorts reveal these effects as irreversible, with photo-oxidative stress from psoralen-UVA adducts accelerating matrix metalloproteinase-mediated collagenolysis over years of cumulative dosing.^[59]

Contraindications and Monitoring

Methoxsalen is contraindicated in patients with hypersensitivity to psoralen compounds or a history of photosensitive reactions to psoralens, as well as those with conditions predisposing to photosensitivity such as systemic lupus erythematosus.^[29]^[60] It is also contraindicated in individuals with active invasive squamous cell carcinoma or melanoma, due to the heightened risk of promoting malignant transformation under UVA exposure.^[61] For the injectable formulation used in extracorporeal photopheresis, aphakia represents an absolute contraindication owing to the substantially elevated risk of retinal damage from unfiltered UVA transmission.^[62] Pregnancy constitutes a relative contraindication, as methoxsalen's mutagenic properties raise concerns for fetal harm despite limited human data showing no definitive increase in teratogenic outcomes or first-trimester losses beyond baseline rates; administration should occur only if potential benefits clearly justify risks, with no reproduction studies conducted in rodents for topical forms.^[63]^[64] Relative contraindications include hepatic insufficiency, where impaired biotransformation may prolong drug clearance and amplify toxicity, necessitating cautious use with dose adjustments or avoidance in severe cases.^[65]^[66] Patients with Fitzpatrick skin types I or II (fair skin prone to burning) warrant relative caution, as they exhibit greater susceptibility to acute phototoxicity and long-term oncogenic risks, though not outright exclusion.^[30] The FDA imposes a black box warning on methoxsalen, emphasizing its use solely under supervision by physicians experienced in photochemotherapy due to the confirmed carcinogenic potential when combined with UVA, including elevated incidences of squamous cell carcinoma and melanoma with cumulative exposure.^[1]^[67] Monitoring protocols mandate baseline and periodic liver function tests, particularly for extended therapy, to detect hepatotoxicity early.^[68] Dermatologic surveillance includes annual comprehensive skin examinations to screen for nonmelanoma skin cancers and melanoma, given the dose-dependent risk escalation.^[1] Ophthalmologic evaluations for cataract formation are recommended, alongside strict caps on cumulative UVA dosimetry—typically below thresholds linked to marked carcinogenicity, such as 1000 J/cm²—to mitigate long-term hazards.^[1] Patients must protect eyes and skin from sunlight post-ingestion until drug clearance, with wraparound UV-blocking eyewear required during daylight hours on treatment days.^[69]

Controversies and Debates

Risk-Benefit Assessments

In patients with refractory psoriasis unresponsive to topical therapies and milder systemic options, PUVA therapy incorporating methoxsalen demonstrates a favorable risk-benefit profile when strictly limited to severe cases, as the potential for substantial symptom remission and quality-of-life improvements offsets elevated long-term risks under controlled protocols.^[70] Empirical models of phototherapies for psoriasis indicate incremental quality-adjusted life-year (QALY) gains at acceptable cost-effectiveness thresholds, though direct PUVA-specific QALY data remain sparse and often bundled with UVB comparisons showing gains below €20,000 per QALY in moderate-to-severe disease.^[71] This net benefit hinges on causal mechanisms where methoxsalen's photoactivation with UVA induces targeted DNA crosslinks in hyperproliferative keratinocytes, achieving clearance rates superior to alternatives in non-responders, but inevitably extending to mutagenic potential that alternatives like biologics may partially avoid.^[2] Subgroup analyses reveal amplified net benefits in younger adults with extensive plaque involvement who fail first-line treatments, where remission durations extend years with fewer cumulative exposures, versus diminished returns in elderly patients (>65 years), where comorbidities exacerbate UVA-induced immunosuppression and skin fragility, elevating complication rates despite comparable short-term efficacy.^[72] For instance, phototherapy erythema incidence remains low (0.46% per session for PUVA), but long-term skin cancer risks—such as squamous cell carcinoma odds ratios exceeding 10-fold after >350 treatments—compound with age-related DNA repair deficits, rendering the therapy's DNA-damaging inevitability less justifiable absent exhaustive prior interventions.^[73]^[74] In milder disease, benefits prove marginal, as topical or narrowband UVB alternatives yield similar clearance with attenuated carcinogenicity, underscoring PUVA's reservation for scenarios where untreated disease morbidity rivals therapy hazards.^[75] Overall, data-driven assessments prioritize PUVA's deployment only post-failure of less genotoxic modalities, with mandatory skin surveillance to mitigate irreversible harms from unrepairable psoralen-DNA adducts, affirming that while efficacy in recalcitrant cases justifies use, the therapy's risk trajectory demands individualized, evidence-tempered application.^[57]^[5]

Criticisms of PUVA Therapy

Critics of PUVA therapy have highlighted its potential for inducing long-term carcinogenicity, particularly squamous cell carcinoma and melanoma, as a basis for restricting or abandoning its use in favor of alternatives. A 1997 prospective cohort study of 1,380 psoriasis patients treated with oral methoxsalen and UVA reported a dose-dependent elevation in melanoma risk, with a relative risk of 2.3 overall and up to 5.4 for those receiving over 250 treatments, observed approximately 15 years post-initiation. This finding fueled debate, with some experts questioning whether the therapy's efficacy justifies continued application given the oncogenic hazards and the advent of systemic alternatives like retinoids and early biologics.^[57]^[76] In the era of biologics, detractors argue PUVA represents an outdated modality overshadowed by targeted immunotherapies that mitigate phototoxic DNA damage without equivalent cumulative cancer risks, though direct head-to-head evidence remains limited. Ethical concerns have also surfaced regarding informed consent, as patients may underestimate persistent oncogenic threats—such as sustained squamous cell carcinoma incidence up to 15 years post-discontinuation—potentially exacerbated by incomplete disclosure of dose-related perils in clinical protocols.^[77]^[78]^[79] Counterarguments emphasize PUVA's non-immunosuppressive profile as undervalued amid biologics' vulnerabilities to opportunistic infections and broader adverse events, positioning it as a viable option for patients intolerant to or failing immunomodulators, provided strict dose limits and monitoring curb misuse. Nonetheless, calls persist for heightened scrutiny of its deployment in profit-oriented settings, where incentives might prioritize short-term clearance over long-term safety data.^[80]^[81]

Historical Development

Discovery and Early Research

Methoxsalen, a naturally occurring furocoumarin, has roots in ancient folk medicine, where extracts from the plant Ammi majus were applied topically to vitiligo lesions in Egypt as early as 2000 BC, followed by controlled sun exposure to induce repigmentation.^[82] Similar practices employing related plants like Psoralea corylifolia were documented in ancient Indian traditions for treating depigmented skin conditions.^[82] These empirical observations highlighted the photosensitizing effects of psoralen-containing plants but lacked isolation of active compounds or mechanistic understanding. The active principle, methoxsalen (also known as 8-methoxypsoralen or xanthotoxin), was first isolated in 1947 from the seeds of Ammi majus by Egyptian chemists Ibrahim Fahmy and Hussein Abu-Shady, who named it "ammoidin."^[83] This extraction from the umbelliferous plant, native to the Mediterranean and Middle East, provided a purified form for further study, confirming its presence as a photoactive furanocoumarin responsible for the historical therapeutic effects.^[8] In the 1950s, methoxsalen entered early clinical use primarily for vitiligo, with oral formulations like Meladinine becoming available in Europe and the United States; doses of 20-40 mg were administered before sunlight exposure to stimulate melanogenesis. Laboratory investigations during this decade, building on prior work with psoralens, elucidated its photoreactivity, demonstrating covalent binding to DNA upon UVA irradiation, which inhibited cell proliferation and enhanced pigmentation.^[84] By the 1960s, controlled studies confirmed its efficacy in repigmentation trials, though side effects like erythema prompted refinements in dosing and light exposure protocols.^[85] The 1970s marked the transition to systemic photochemotherapy, termed PUVA (psoralen plus UVA), pioneered through collaborative efforts by Klaus Wolff in Vienna and Thomas B. Fitzpatrick in Boston. Initial trials applied oral methoxsalen (0.6 mg/kg) followed by high-intensity UVA lamps, showing rapid clearance of psoriatic plaques in small cohorts.^[86] A pivotal 1974 report in the New England Journal of Medicine detailed open-label results in 10 psoriasis patients, where 8 achieved complete clearing after an average of 25 treatments, with paired comparisons favoring PUVA over oxychinoline alone.^[87] These findings established methoxsalen's role in modulating epidermal hyperproliferation via DNA cross-linking, setting the stage for larger efficacy validations.^[87]

Regulatory Milestones

Methoxsalen received initial U.S. Food and Drug Administration (FDA) approval in 1954 for the treatment of vitiligo, marking its early recognition as a photosensitizing agent for dermatological conditions.^[88] In 1982, the FDA expanded approval to include its use in combination with ultraviolet A (UVA) radiation—known as PUVA therapy—for refractory psoriasis, with subsequent inclusion for cutaneous T-cell lymphoma (CTCL) based on demonstrated efficacy in controlled studies.^[89]^[90] This expansion required specialized administration protocols to mitigate phototoxicity risks. By the 1980s, accumulating evidence of long-term carcinogenicity prompted the FDA to impose a black box warning on methoxsalen labels, emphasizing its use only by physicians experienced in photochemotherapy and mandating patient monitoring for skin cancer and cataracts.^[91]^[31] The warning highlighted dose-dependent increases in squamous cell carcinoma risk, supported by post-approval surveillance data from PUVA cohorts, and contraindicated its use in patients with photosensitivity disorders or prior arsenic/ionizing radiation exposure.^[1] In the European Union, methoxsalen followed a comparable regulatory trajectory under the European Medicines Agency (EMA) framework, with approvals for PUVA in psoriasis and vitiligo dating to the mid-20th century via national authorizations, later harmonized for extracorporeal photopheresis in CTCL and graft-versus-host disease.^[92] Specific formulations, such as sterile solutions for photopheresis, received EMA or national renewals into the 21st century, with ongoing requirements for risk management plans addressing oncogenicity.^[93] International variances persist, such as later approvals in regions like Australia in 2019 for CTCL photopheresis, reflecting niche retention amid safer alternatives.^[94] Despite periodic safety reviews, no widespread withdrawals occurred, as its efficacy in recalcitrant cases outweighed risks under strict oversight.^[95]

Current Use and Research Directions

Formulations and Availability

Methoxsalen is available in oral capsule form, typically as 10 mg soft gelatin capsules designed for systemic absorption in PUVA therapy.^[65] Branded products such as Oxsoralen-Ultra utilize a liquid-filled capsule formulation to enhance bioavailability compared to earlier crystalline forms.^[96] Dosage strengths generally range from 10 mg to 40 mg for oral use, administered 1.5 to 2 hours prior to UVA exposure at 0.4 mg/kg body weight.^[30] Topical formulations include a 1% lotion, marketed as Oxsoralen, applied directly to depigmented skin areas for vitiligo treatment in conjunction with controlled UVA or sunlight exposure.^[97] For extracorporeal photopheresis, an injectable sterile solution containing 20 mcg/mL methoxsalen, branded as Uvadex, is used to treat conditions like cutaneous T-cell lymphoma.^[98] In the United States and European Union, methoxsalen is classified as a prescription-only medication, restricted to supervised use due to its photosensitizing properties and associated risks.^[31] Generic equivalents of oral capsules and topical forms have been approved and available since the late 1990s, following the expiration of key patents for branded products like Oxsoralen.^[99] Pricing for generic 10 mg oral capsules in the US typically exceeds $1,400 for a 50-capsule supply, reflecting limited manufacturing scale and demand.^[100] Branded formulations command higher costs, while international generic options can be substantially lower, around $1 per tablet in select markets.^[101] No widespread shortages have been reported in the 2020s, though supply chain constraints for specialized photosensitizers remain a general concern in dermatology.^[102]

Recent Developments and Future Prospects

In 2018, researchers synthesized analogs of methoxsalen by conjugating seven distinct cytotoxic pharmacophores to its 5-amino position, demonstrating enhanced cytotoxicity in both photoactivated and non-photoactivated conditions against cancer cell lines, potentially expanding its utility beyond dermatological applications.^[20] Clinical exploration of methoxsalen in extracorporeal photopheresis (ECP) for chronic graft-versus-host disease (cGVHD) continued, with a 2019 prospective randomized trial establishing ECP with methoxsalen as a viable first-line option under NIH consensus criteria, achieving response rates in refractory cases.^[103] A 2025 prospective study further evaluated oral PUVA's effectiveness in cutaneous cGVHD, reporting partial to complete responses in a majority of patients with manageable side effects.^[104] Advances in PUVA protocols include bath-PUVA variants, analyzed in a 2025 large-scale retrospective study of over 1,000 psoriasis patients, which showed sustained efficacy independent of comorbidities like obesity or smoking, with lower systemic exposure compared to oral methoxsalen.^[38] A 2022 network meta-analysis of 32 studies involving 2,120 psoriasis patients affirmed PUVA's comparable efficacy to other UV therapies but highlighted its targeted role for recalcitrant cases amid the rise of biologic agents.^[105] These findings underscore refined dosing and delivery to mitigate overdose risks, though long-term carcinogenic concerns persist. Future prospects for methoxsalen remain constrained by its established safety profile, limiting broad expansion in favor of safer alternatives like biologics; however, its cost-effectiveness and equipment-based delivery position it as a valuable option in low-resource environments where advanced immunotherapies are inaccessible, as evidenced by consistent outcomes in diverse patient cohorts without reliance on expensive systemic drugs.^[38] Ongoing refinements in photopheresis applications may sustain niche roles in hematologic conditions, pending further randomized data on long-term outcomes.

References

[1]
[PDF] 09048slr037_methoxsalen_lbl.pdf - accessdata.fda.gov
Methoxsalen with UV radiation should be used only by physicians who have special competence in the diagnosis and treatment of psoriasis and vitiligo and who ...
[2]
METHOXSALEN PLUS ULTRAVIOLET A RADIATION - NCBI - NIH
Methoxsalen is used in conjunction with controlled exposure to UVA radiation for the symptomatic treatment of severe, recalcitrant, disabling psoriasis.Missing: pharmacology | Show results with:pharmacology
[3]
[PDF] RoC Profile: Methoxsalen with Ultraviolet A Therapy
Methoxsalen is now used in combination with UVA in the treatment of vitiligo, se- vere psoriasis, atopic dermatitis, alopecia areata, lichen planus, ur- ticaria ...
[4]
PUVA-induced lymphocyte apoptosis: mechanism of action in ...
Previous studies have suggested that PUVA's mechanism of action in psoriasis is a result of its direct lymphotoxic effects.
[5]
Methoxsalen with Ultraviolet A Therapy - 15th Report on Carcinogens
Methoxsalen is now used in combination with UVA in the treatment of vitiligo, severe psoriasis, atopic dermatitis, alopecia areata, lichen planus, urticaria ...
[6]
8-Methoxypsoralen | C12H8O4 | CID 4114 - PubChem
Methoxsalen is a member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group.
[7]
METHOXSALEN - precisionFDA
Chemical Structure ; Stereochemistry. ACHIRAL ; Molecular Formula. C12H8O ; Molecular Weight. 216.19 ; Optical Activity. NONE ; Defined Stereocenters. 0 / 0.Missing: IUPAC | Show results with:IUPAC
[8]
[PDF] nda 20-969 - accessdata.fda.gov
Methoxsalen, the drug substance, is a naturally-occurring, photoactive substance found in the seed of the Ammi majus (umbelliferae) plant; it belongs to a class ...
[9]
METHOXSALEN - ScienceDirect.com
The method is based on extraction of the plasma, acidified with hydrochloric acid, with benzene-ethyl acetate mixture (9:l) and the solvent is evaporated, to ...
[10]
Psoralen - an overview | ScienceDirect Topics
Psoralen and psoralen derivatives are found in the seeds of Psoralea corylifolia and in the root of Ammi majus, and in other vegetation such as limes, figs, ...
[11]
Botanical Sources, Chemistry, Analysis, and Biological Activity of ...
In plants, furanocoumarins play a key role as phytoalexins and they are known for their preeminent involvement in both constitutive and induced plant defense, ...
[12]
[PDF] Selected phenolic compounds in cultivated plants: ecologic ...
Sep 23, 1998 · marmesin is the primary antimicrobial agent. UV radiation (<400 nm) induces the synthesis of furanocoumarins, which are often produced in tissue ...
[13]
Gut Metabolism of Furanocoumarins: Proposed Function of Co O ...
Nov 17, 2020 · It is widely believed that furanocoumarins play an important role in plant defense mechanisms against herbivores. In turn, some insects also ...
[14]
Biosynthesis and heterologous production of furanocoumarins
Nov 11, 2020 · In this paper, we review the natural conversion of amino acids into furanocoumarins, as well as the heterologous expression of each enzyme of the pathway.Missing: enzymatic | Show results with:enzymatic
[15]
Molecular Cloning and Functional Characterization of Psoralen ...
The flow of carbon in furanocoumarin biosynthesis is known since decades from precursor feeding studies (1) and proceeds from 4-coumaric acid via umbelliferone, ...
[16]
Chemistry and health effects of furanocoumarins in grapefruit - NIH
In the first step of coumarin synthesis, several phenylpropanoid intermediates are synthesized from phenylalanine (Figure 1). Through a deamination reaction by ...
[17]
Three types of enzymes complete the furanocoumarins core ...
The p-coumaroyl CoA is subsequently transformed into the pivotal intermediate (umbelliferone) in the synthesis of FCs catalyzed by a 2-oxoglutarate-dependent ...
[18]
Molecular cloning and functional characterization of psoralen ...
Jan 5, 2007 · Psoralen synthase catalyzes a unique carbon-chain cleavage reaction concomitantly releasing acetone by syn-elimination. Related plants, i.e. ...Missing: umbelliferone | Show results with:umbelliferone
[19]
Biosynthesis of linear furanocoumarins - Canadian Science Publishing
The unsubstituted furanocoumarin psoralen is formed first, and hydroxylation and O-methylation then lead to methoxy-substituted derivatives, with other ...
[20]
Synthetically Modified Methoxsalen for Enhanced Cytotoxicity ... - NIH
Dec 22, 2018 · The natural product furocoumarin, known as methoxsalen or 8-MOP, has a long history as a nonionic reversible DNA intercalator which demonstrates ...Missing: photoaddition | Show results with:photoaddition
[21]
The Effect of Psoralens on Hepatic and Cutaneous Drug ...
These light-activated cycloaddition prod- ucts are formed between the 3,4, or 4' ,5', position of the psoralen molecule and the 5,6 position of pyrimidine bases ...
[22]
Psoralen Derivative - an overview | ScienceDirect Topics
Mechanism of Action. Psoralens rapidly penetrate into the cell and intercalate between DNA base pairs and, on exposure to UVA radiation, cause a linkage of ...Missing: photoaddition | Show results with:photoaddition
[23]
Spectroscopic view on the interaction between the psoralen ...
Mar 8, 2024 · As outlined in the Introduction, intercalation is a requirement for photoaddition to DNA and thus is crucial for the photoreactive potential of ...
[24]
Tracing the Photoaddition of Pharmaceutical Psoralens to DNA - MDPI
The DNA is represented by the thymine base. The mechanism of this photoaddition was addressed by steady-state [11] and time-resolved spectroscopy [16,17,18] ...Missing: methoxsalen | Show results with:methoxsalen
[25]
Psoralen: a narrative review of current and future therapeutic uses
Mar 15, 2024 · Once activated, psoralens form mono- and di-adducts with DNA, leading to marked cell apoptosis. This apoptotic effect is more pronounced in ...
[26]
Methoxsalen Monograph for Professionals - Drugs.com
Oct 22, 2024 · Methoxsalen occurs naturally in several different plants including Ammi majus (Umbelliferae), Psorales coryfolia, and Ruta chalepensis, but ...
[27]
Clinical Pharmacokinetics of Methoxsalen and Other Psoralens
The drug has a high, but variable, intrinsic metabolic clearance and is almost completely metabolised. Serum elimination half-life is in the order of 0.5 to 2 ...
[28]
Methoxsalen: Uses, Interactions, Mechanism of Action - DrugBank
It binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
[29]
[PDF] UVADEX® (Methoxsalen) STERILE SOLUTION, 20 mcg/mL ...
Mechanism of action: The exact mechanism of action of methoxsalen is not known. The best-known biochemical reaction of methoxsalen is with DNA. Methoxsalen ...
[30]
Methoxsalen (oral route) - Side effects & dosage - Mayo Clinic
Jul 31, 2025 · This treatment is called photopheresis and is used to treat the skin problems associated with mycosis fungoides, which is a type of lymphoma.
[31]
8MOP, Oxsoralen (methoxsalen) dosing, indications, interactions ...
methoxsalen increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ... Half-Life: 0.75-2.4 hr. Onset: 1-2 hr. Duration: 3-8 ...
[32]
The Patient's Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy
Jul 29, 2016 · For hand and foot soak PUVA, patients will use their measuring cup to mix 10 mg of methoxsalen with 2 quarts of warm water for just hands or ...
[33]
Phototherapy. UVA photo(chemo)therapy - DermNet
Mechanism of action ... Psoralen interacts with ultraviolet radiation in the epidermis to form DNA photo-adducts. Maximum activity occurs at a wavelength of 325 ...
[34]
Phototherapy - ScienceDirect.com
During the last phase, the maintenance one, the frequency and dose of treatment are kept constant. ... maximum cumulative dose of 1000–1500 J/cm). There is also ...
[35]
https://escholarship.ucop.edu/uc/item/2ts6s057
[36]
Clinical Severity of Psoriasis in Last 20 Years of PUVA Study
The PUVA Follow-up Study is a long-term safety and efficacy study that has prospectively studied 1380 patients with moderate to severe psoriasis who were first ...
[37]
Comparison of Phototherapy (UV-B) and Photochemotherapy ...
Patients treated with PUVA, in the initial and maintenance period, achieved in general a higher therapeutic score (95% to 100% clearance) than those receiving ...
[38]
A Large‐Scale, Retrospective Analysis of Bath‐Psoralen Plus ... - NIH
Aug 13, 2025 · The mean baseline PASI score was 24.9. Bath‐PUVA achieved PASI 75 in 80.4% of patients, PASI 90 in 44.1%, and PASI 100 in 2.6%, with efficacy ...
[39]
[Long-term effects of PUVA therapy on Israeli patients with vitiligo]
Long-term treatment with PUVA for vitiligo patients does not entail photoaging damages or increased risk of skin cancer.Missing: cohort | Show results with:cohort
[40]
Phototherapy for vitiligo: A narrative review on the clinical and ...
Apr 17, 2024 · In a study comparing PUVA and PUVAsol for generalized vitiligo, PUVA demonstrated higher efficacy (46.4% mean percentage change in BSA at 36 ...
[41]
8-Methoxypsoralen Plus Ultraviolet A Reduces the Psoriatic ...
Similar to the effect of PUVA on overall macroscopic skin thickness, the effect of PUVA in reducing epidermal hyperplasia was partially sustained, whereas the ...
[42]
Joint American Academy of Dermatology–National Psoriasis ...
Jul 25, 2019 · ... PUVA, finding enhanced efficacy, fewer treatment sessions, and lower cumulative UVA and UVB doses than with either treatment alone. 59 ...<|separator|>
[43]
Randomized Double-blind Trial of the Treatment of Chronic Plaque ...
Objective To compare the efficacy of oral psoralen–UV-A (PUVA) therapy with that of narrowband UV-B (NB-UVB) therapy in patients with chronic plaque psoriasis.
[44]
A randomized comparison of narrow-band TL-01 phototherapy and ...
Only 12% of those treated with TL-01 were clear of psoriasis 6 months after finishing treatment compared with 35% for PUVA (P = . 002). Conclusion: When given ...Missing: relapse | Show results with:relapse<|separator|>
[45]
Efficacy of psoralen plus ultraviolet A therapy vs. biologics ... - PubMed
Conclusions: Retrospective analysis of registry data revealed that the primary efficacy of PUVA was superior to that of certain biologics.Missing: effectiveness | Show results with:effectiveness
[46]
The long-term efficacy and safety of new biological therapies ... - NIH
Psoriasis clinical trials revealed no evidence of increased risk of opportunistic infections, tuberculosis, or skin cancers during up to 60 weeks of etanercept ...
[47]
Psoriasis Treatment Cost Comparison: Biologics Versus Home ...
Feb 2, 2018 · Results: Secukinumab is the most expensive biologic with a 3-year cost of $182,718 compared with a 3-year cost of $5,000 for phototherapy.<|separator|>
[48]
A Perspective on the Use of NB-UVB Phototherapy vs. PUVA ...
Jul 1, 2018 · For the treatment of vitiligo, NB-UVB has been shown to be superior to PUVA with respect to rates of repigmentation, particularly for unstable ...Missing: cohort | Show results with:cohort<|separator|>
[49]
THE BENEFITS AND RISKS OF LONG-TERM PUVA ...
The long-term changes with PUVA therapy involve all of the skin such as epidermal maturation disorder, activation of melanocytes, and degeneration of dermal ...
[50]
Minimising the risks of PUVA treatment - PubMed
The short term adverse effects include erythema, pruritus, nausea and headache. While short term adverse effects are limited and reversible after ...
[51]
Methoxsalen Side Effects: Common, Severe, Long Term - Drugs.com
Aug 17, 2025 · There is an increased risk of developing skin cancer after use of methoxsalen. You should check your body regularly and show your doctor any ...
[52]
PUVA-induced phototoxicity: Incidence and causes - ScienceDirect
Background: Phototoxicity is the most significant short-term adverse effect of PUVA therapy. ... Possible adverse effects of oral PUVA include erythema ...
[53]
Burns caused by accidental overdose of photochemotherapy (PUVA)
Over a 8-year period, seven cases of accidental overexposure of PUVA occurred at our hospital, with an incidence of 0.05%. The age range of the patients was ...
[54]
PUVA (photochemotherapy) - DermNet
PUVA or photochemotherapy is a type of ultraviolet radiation treatment (phototherapy) used for severe skin diseases.
[55]
Allergic contact and photocontact dermatitis due to psoralens in ...
Of 371 patients treated with 8MOP, three (0.8%) developed an acute dermatitis in the PUVA-treated areas. This incidence was significantly lower (P less than 0. ...
[56]
Risk of Squamous Cell Carcinoma and Methoxsalen (Psoralen) and ...
Reports from this multicenter study have demonstrated that in this population long-term exposure to PUVA increases the risk of squamous cell carcinoma (SCC) ...
[57]
Malignant Melanoma in Patients Treated for Psoriasis with ...
Apr 10, 1997 · Photochemotherapy with oral methoxsalen (psoralen) and ultraviolet A radiation (PUVA) is an effective treatment for psoriasis.
[58]
Genital Tumors among Men with Psoriasis Exposed to Psoralens ...
Apr 19, 1990 · Patients with psoriasis treated with PUVA have a dose-dependent increase in the risk of squamous-cell carcinoma on all parts of the body exposed ...
[59]
Methoxsalen (topical route) - Side effects & dosage - Mayo Clinic
Jul 31, 2025 · Methoxsalen belongs to the group of medicines called psoralens. It is used along with ultraviolet light (found in sunlight and some special lamps)Missing: eye contraception Fitzpatrick
[60]
Methoxsalen: Side Effects, Uses, Dosage, Interactions, Warnings
What Are Warnings and Precautions for Methoxsalen? · Hypersensitivity to psoralen compounds · Photosensitive disease states (SLE, etc.), history of melanoma, ...
[61]
Oxsoralen Disease Interactions - Drugs.com
The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a ...
[62]
[PDF] UVADEX- methoxsalen injection, solution - accessdata.fda.gov
UVADEX™ (methoxsalen) Sterile Solution should be used only by physicians who have special competence in the diagnosis and treatment of cutaneous T-cell lymphoma ...
[63]
Outcomes of pregnancies among women and partners of men with a ...
Because oral methoxsalen and UV-A radiation (PUVA) therapy is mutagenic, concern exists about the potential for teratogenic effects resulting from the use ...
[64]
Methoxsalen Use During Pregnancy - Drugs.com
Jul 28, 2025 · Methoxsalen Pregnancy Warnings: Safety has not been established during pregnancy. This drug should be used during pregnancy only if clearly needed.Missing: teratogenic | Show results with:teratogenic
[65]
Methoxsalen: Package Insert / Prescribing Information - Drugs.com
HEPATIC DISEASES: Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.
[66]
8-MOP (Methoxsalen): Side Effects, Uses, Dosage, Interactions ...
Hepatic Diseases: Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.
[67]
[PDF] Oxsoralen-Ultra (methoxsalen) - Anthem Providers
Note: Methoxsalen has a black box warning that concurrent use with UV radiation should only be used by physicians who have special competence in diagnosis ...
[68]
Photochemotherapy (PUVA) in psoriasis and vitiligo
Psoriasis: PUVA has been found to be effective in psoriasis in well-conducted studies and randomized controlled trials. It is a relatively safe modality for the ...<|separator|>
[69]
Psoralen plus ultraviolet A (PUVA) photochemotherapy - UpToDate
Jan 24, 2025 · CLINICAL INDICATIONS FOR PUVA · TREATMENT PROTOCOLS · Oral PUVA · - Initial treatment (clearance phase) · - Maintenance treatment · - Treatment ...<|separator|>
[70]
THE BENEFITS AND RISKS OF LONG-TERM PUVA ...
In some individuals, PUVA therapy is more difficult because of skin phototoxicity reactions in the form of severe erythema, edema, and even blistering; ...
[71]
Cost effectiveness of home ultraviolet B phototherapy for psoriasis
Apr 20, 2010 · Incremental costs per QALY gained were €9276 and €4646 respectively, both amounts well below the normally accepted standard of €20 000 per QALY.
[72]
The efficacy and safety of phototherapy in geriatric patients - NIH
This study showed that phototherapy is effective and reliable in the elderly population with proper dose increases and close follow-up.
[73]
(PDF) The efficacy and safety of phototherapy in geriatric patients
May 20, 2025 · The erythema rate was found to be 0.43% per session for NB-UVB treatment and 0.46% per session for PUVA treatment as a side effect. Study ...
[74]
The risk of squamous cell and basal cell cancer associated with ...
Jan 20, 2012 · Exposure to more than 350 PUVA treatments greatly increases the risk of SCC. Exposure to fewer than 150 PUVA treatments has, at most, modest ...
[75]
Risk of Skin Cancer with Phototherapy in Moderate-to-Severe ...
Risk of skin cancer in psoriasis patients receiving long-term narrowband ultraviolet phototherapy: Results from a Taiwanese population-based cohort study.
[76]
Malignant melanoma in patients treated for psoriasis with ... - PubMed
About 15 years after the first treatment with PUVA, the risk of malignant melanoma increases, especially among patients who receive 250 treatments or more.
[77]
Should PUVA Be Abandoned? | New England Journal of Medicine
Apr 10, 1997 · PUVA induces remission of psoriasis through repeated, controlled phototoxic reactions that occur only when psoralens are photoactivated by ultraviolet A.
[78]
Should PUVA be abandoned? - PubMed
Should PUVA be abandoned? ... N Engl J Med. 1997 Apr 10;336(15):1090-1. doi: 10.1056/NEJM199704103361509.Missing: NEJM cancer
[79]
https://jwatch.org/jd200309090000002/2003/09/09/cancer-risk-persists-after-puva
[80]
Role of phototherapy in the era of biologics - PMC - PubMed Central
In a systematic review by Almutawa et al, oral PUVA achieved the highest clearance rate (CR) (79%) but caused symptomatic erythema and blistering in 17% of ...Missing: criticisms non-
[81]
Risk of Serious Adverse Events Associated With Biologic and ...
A meta-analysis of RCTs of biologics for any indication has shown that they are associated with adverse events more frequently than the control agents are, ...
[82]
Psoralen therapy in vitiligo - ScienceDirect.com
In 1947 several crystalline compounds, including ammoidin (8-methoxypsoralen) and bergapten (5-methoxypsoralen), were isolated from the powder of Ammi majus L.
[83]
Methoxsalen - an overview | ScienceDirect Topics
Methoxsalen (UVADEX) is a naturally occurring photoactive substance found in the seed of the Ammi majus plant and belongs to a class of compounds known as ...
[84]
Photoallergy - an overview | ScienceDirect Topics
Studies in the 1950s and 1960s revealed that a reaction took place between FCs and the skin, in the presence of UV light (Musajo et al 1953, 1954, 1966 ...
[85]
PSORALEN PHOTO CHEMOTHERAPY OF CUTANEOUS ...
Two such prospective studies in the early 1960s of 173 and 92 volunteers treated with 20 mg of 8-MOP or placebo at breakfast followed by ad lib sun exposure ...
[86]
The history of photochemotherapy - PubMed
In this century, extensive research on psoralens started in Egypt, where the active ingredients were isolated from plants and were soon thereafter ...
[87]
Photochemotherapy of Psoriasis with Oral Methoxsalen and ...
Dec 5, 1974 · In 16 of these cases, a paired comparison showed methoxsalen followed by longwave ultraviolet light to be more effective than conventional ...Missing: discovery | Show results with:discovery
[88]
https://www.drugpatentwatch.com/p/generic-api/methoxsalen
[89]
Psoralen - LiverTox - NCBI Bookshelf - NIH
Jan 16, 2020 · 8-methoxsalen and 5-methoxsalen are furocoumarins referred to collectively as psoralens that have photosensitizing activity and are used orally ...
[90]
Guidelines of care for the management of psoriasis and&nbsp
Oct 8, 2009 · Early studies demonstrated the efficacy of BB-. UVB monotherapy in psoriasis. One study reported resolution of psoriasis in 20 of 28 patients ...
[91]
Methoxsalen (Systemic) (Professional Patient Advice) - Drugs.com
Oct 13, 2025 · There is no clinical evidence to show that treatment with methoxsalen for more than 6 months or using a different schedule provides additional ...Missing: cycloaddition spectroscopy
[92]
Community Register of orphan medicinal products
Designation number: EU/3/06/374. Active substance: Methoxsalen. Indication: Treatment of Graft-versus-Host disease. Sponsor: Therakos Europe Limited
[93]
Methoxsalen G.L. Pharma 20 micrograms/ml solution for blood ...
Marketing authorisation number(s). PL 21597/0027. 9. Date of first authorisation/renewal of the authorisation. 20/10/2019. 10. Date of revision of the text. 20 ...Missing: approval | Show results with:approval
[94]
Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in ...
Oct 31, 2019 · UVADEX (methoxsalen) has received regulatory approval in Australia by the Therapeutic Goods Administration (TGA) for extracorporeal administration with the ...
[95]
[PDF] Australian Public Assessment Report for Methoxsalen
Nov 14, 2019 · The product has been approved in multiple foreign markets for the treatment of cutaneous. T cell lymphoma (CTCL), including the United States ( ...
[96]
Oxsoralen-Ultra: Package Insert / Prescribing Information - Drugs.com
Oxsoralen-Ultra represents a new dose form of methoxsalen. This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier ...
[97]
Oxsoralen (Methoxsalen Lotion): Side Effects, Uses, Dosage ... - RxList
Oxsoralen (methoxsalen lotion) is a topical repigmenting agent used in vitiligo in conjunction with controlled doses of ultraviolet A (320-400 nm) or sunlight.
[98]
[PDF] UVADEX (Methoxsalen) - accessdata.fda.gov
Use of the UVAR and UVAR XTS® Systems after oral administration of methoxsalen were previously approved for the treatment of Cutaneous T-Cell Lymphoma.
[99]
Generic Oxsoralen Availability - Drugs.com
Oct 8, 2025 · Generic Oxsoralen Availability. Last updated on Oct 8, 2025. Oxsoralen is a brand name of methoxsalen topical, approved by the FDA in the ...Missing: EU | Show results with:EU
[100]
Methoxsalen Prices, Coupons, Copay Cards & Patient Assistance
Oral Capsule. 10 mg methoxsalen oral capsule from $1,433.41 for 50 capsules ; from $1,433.41 for 50 capsules ; Hadlima. Hadlima is used for ankylosing spondylitis ...
[101]
Methoxsalen Prices - U.S. & International | PharmacyChecker.com
4.7 367 $44.99 40 tablets $1.12 per tablet Free Shipping. Ships Worldwide from Australia, Canada, Mauritius, New Zealand, United Kingdom
[102]
https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
[103]
Randomized controlled study of ECP with methoxsalen as first-line ...
Jul 22, 2019 · This is the first prospective, randomized study investigating ECP as a first-line therapy in cGVHD using the 2015 NIH consensus criteria.
[104]
Effectiveness of Oral Psoralen + UV-A (PUVA) Therapy in the ...
Feb 12, 2025 · This study primarily aims to evaluate the effectiveness and safety of oral PUVA therapy in patients diagnosed as chronic cutaneous GVHD.
[105]
Assessment of efficacy and safety of UV-based therapy for psoriasis
Jan 6, 2022 · A meta-analysis published in 2013 comparing the efficacy of localized phototherapies showed that topical PUVA treatment is more effective than ...